|Bid||157.75 x 900|
|Ask||175.33 x 800|
|Day's range||170.48 - 172.36|
|52-week range||142.81 - 256.80|
|PE ratio (TTM)||N/A|
|Earnings date||1 Aug 2018 - 6 Aug 2018|
|Forward dividend & yield||2.88 (1.66%)|
|1y target est||207.00|
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
Allergan (AGN) posts positive top-line data from a phase III study on Bimatoprost SR, a biodegradable implant for reducing IOP in patients with open-angle glaucoma or ocular hypertension.
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Stein ...
Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Stocks that moved substantially or traded heavily Thursday: J.M. Smucker Co., down $5.72 to $100.80 The packaged food company had a weak fourth quarter and gave disappointing forecasts for the current ...
TOKYO (AP) — Asian shares were moderately lower Friday, as investors awaited the Group of Seven leaders' meeting, continuing into the weekend, and for European Central Bank and Federal Reserve meetings next week.
Carl Icahn has built a small position in Allergan Plc, according to people familiar with the matter, as the drugmaker plans to spin off its women’s health and antibiotic divisions. Icahn previously held a position in Allergan, disclosing a stake in 2016 that was sold in the first quarter of 2017, according to data compiled by Bloomberg. Allergan rose as much as 3.3 percent in late trading in New York on the news before settling at about $159, up about 2.3 percent from Wednesday’s close.
Allergan (AGN), with headquarters in Dublin, Ireland, is one of the leading pharmaceutical companies. It deals in both generic and specialty pharmaceutical products. Its US administrative headquarters are in Parsippany, New Jersey.
Allergan (AGN) responds to shareholders stating that it is open to the latter's opinions. However, the company has requested them to vote against appointment of independent chairman.
Allergan plc’s (NYSE:AGN): Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The US$51.26B market-cap posted a loss in itsRead More...
Activist investor Appaloosa and hedge fund Senator Investment Group asked Allergan PLC for management changes early Tuesday, requesting that the company either split the office of chief executive and chairman -- two positions that Brent Saunders holds -- or get a new, outside chairman or CEO, among other options. In a letter to Allergan's board of directors, signed by Appaloosa President and Chief Executive David Tepper and Senator Investment Group Managing Partner Douglas Silverman, the financial firms described Allergan's recent strategic review as underwhelming.
Allergan Plc faced a skeptical appeals court Monday as the company defended its use of an American Indian tribe’s sovereign immunity to avoid challenges to its patents from generic-drug makers. Two of three judges on the U.S. Court of Appeals for the Federal Circuit in Washington questioned whether Allergan was seeking to circumvent review by the Patent and Trademark Office. The reviews are widely used by technology companies, banks and insurers who say it offers a way to weed out bad patents.
Amgen and Allergan were sidelined Friday after the FDA delayed their Herceptin biosimilar, giving Roche's blockbuster breast cancer drug some breathing room.
On May 31, Viking Therapeutics (VKTX), a California-based biotechnology firm, closed at $9.99—a rise of ~101% from the previous day’s closing price of $4.97. The stock price nearly doubled on the news of the positive Phase-II clinical trial results from Madrigal Pharmaceuticals’ (MDGL) NASH (non-alcoholic steatohepatitis) candidate MGL-3196. The news triggered a rise of ~150% in Madrigal Pharmaceuticals’ stock price. On the same day, the SPDR S&P Biotech ETF (XBI) rose ~1.5%.
Botox maker Allergan is looking to sell its women's health and infectious diseases units, but it won't engage in a "fire sale" to do so, Chief Executive Brent Saunders said Wednesday.
“Bold” is Allergan PLC's adjective of choice, trotted out frequently by CEO Brent Saunders and others at the Botox maker. Disposing of two minor units won’t address broader concerns that have seen Allergan’s shares decline by more than 40 percent from last year’s highs.
Allergan (AGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy. The company says four placebo pills were placed out of order in the Taytulla packs. Allergan says the first four days of therapy had four non-hormonal placebo capsules instead of active capsules.
Allergan is voluntarily recalling packs of its birth control pills in the U.S. because of a packaging error with placebos, increasing the possibility of unintended pregnancy.
Allergan PLC is recalling one lot of the birth control Taytulla because the first four days of the therapy erroneously placed placebo pills where contraceptive capsules should have been. Patients concerned about this should consult their doctor, Allergan said. The packaging error affected one lot of Taytulla, according to Allergan, a "physicians sample pack" that was distributed nationwide.